Akebia Therapeutics, Inc. (AX9.F)
- Previous Close
2.1580 - Open
2.2600 - Bid 2.2620 x 30000
- Ask 2.2960 x 30000
- Day's Range
2.2600 - 2.2600 - 52 Week Range
0.7780 - 2.5880 - Volume
3,244 - Avg. Volume
503 - Market Cap (intraday)
635.367M - Beta (5Y Monthly) 0.88
- PE Ratio (TTM)
-- - EPS (TTM)
-0.2900 - Earnings Date Aug 6, 2025 - Aug 11, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. Its product portfolio includes Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent (DD) and non-dialysis dependent (NDD) patients; and Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD and the treatment of iron deficiency anemia in adult patients with NDD-CKD. The company is also developing AKB-9090 for treating cardiac surgery-related acute kidney injury and acute respiratory distress syndrome; and AKB-10108 for the treatment of retinopathy of prematurity in neonates. The company has license and collaboration agreements with Mitsubishi Tanabe Pharma Corporation for the development and commercialization of Vafseo in Japan and other Asian countries. Akebia Therapeutics, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.
www.akebia.com181
Full Time Employees
December 31
Fiscal Year Ends
Sector
Recent News: AX9.F
View MorePerformance Overview: AX9.F
Trailing total returns as of 5/9/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: AX9.F
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: AX9.F
View MoreValuation Measures
Market Cap
594.91M
Enterprise Value
591.14M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
3.02
Price/Book (mrq)
--
Enterprise Value/Revenue
3.59
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-43.33%
Return on Assets (ttm)
-12.49%
Return on Equity (ttm)
--
Revenue (ttm)
160.18M
Net Income Avi to Common (ttm)
-69.41M
Diluted EPS (ttm)
-0.2900
Balance Sheet and Cash Flow
Total Cash (mrq)
51.87M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
17.83M